| Clinical characteristics and PTPN22 1858C/T variant analysis in Jordanian Arab vitiligo patients. | |
| | |
MedLine Citation:
|
PMID: 20560680 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVE: Vitiligo is an autoimmune polygenic disorder, characterized by loss of pigmentation due to melanocyte destruction. Multiple genes and environmental triggers are thought to play a role in inducing vitiligo. These genes and environmental factors differ across different populations. In this study, we investigated vitiligo patients in Jordan for patient characteristics and analyzed the association of the 1858C/T (rs2476601, R620W) variant of the PTPN22 gene with vitiligo in our patients. METHODS: Fifty-five patients with generalized vitiligo and 85 matched normal control subjects who did not have vitiligo or any apparent autoimmune disorder were recruited and interviewed for clinical and demographic characteristics. DNA samples were obtained from patients and controls and genotyped by restriction fragment length polymorphism for the 1858C/T variant. Fifty-three percent of our patients (29 of 55 overall) were female, the average age at onset was 19.2 years, 84.3% of patients (43 of 51 reported) had changing size of depigmented patches, 3.8% (2 of 53 reported) had other autoimmune disease, and 19.2% (5 of 26 reported) had a family history of vitiligo. RESULTS: The allelic frequency of 1858T (620W) was 1.9% in patients as opposed to 2.9% in controls (p = 0.5). No PTPN22 1858 TT homozygotes were observed among patients or controls; 3.8% of vitiligo patients were 1858 CT heterozygotes compared with 5.9% of controls (p = 0.7). Consequently, no significant association was observed between the 1858C/T functional variant and vitiligo patients. CONCLUSION: Although the PTPN22 1858C/T variant has been reported to play a role in increasing the risk of vitiligo in Caucasian patients, it does not appear to play a similar role in the Jordanian population, though a larger cohort of patients might be needed to confirm such a conclusion. |
| | |
Authors:
|
Asem Alkhateeb; Firas Qarqaz; Jude Al-Sabah; Tasnim Al Rashaideh |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Molecular diagnosis & therapy Volume: 14 ISSN: 1179-2000 ISO Abbreviation: Mol Diagn Ther Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-21 Completed Date: 2011-01-18 Revised Date: 2013-05-16 |
Medline Journal Info:
|
Nlm Unique ID: 101264260 Medline TA: Mol Diagn Ther Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 179-84 Citation Subset: IM |
Affiliation:
|
Biotechnology and Genetic Engineering Department, Jordan University of Science and Technology, Irbid, Jordan. asemalkhateeb@just.edu.jo |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Alleles Arabs / genetics* Female Humans Jordan Male Polymorphism, Single Nucleotide / genetics* Protein Tyrosine Phosphatase, Non-Receptor Type 22 / genetics* Vitiligo / enzymology*, genetics* Young Adult |
| Chemical | |
Reg. No./Substance:
|
EC 3.1.3.48/PTPN22 protein, human; EC 3.1.3.48/Protein Tyrosine Phosphatase, Non-Receptor Type 22 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes.
Next Document: Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation s...